Selective inhibition of protein kinase C β2 attenuates the adaptor P66Shc-mediated intestinal ischemia-reperfusion injury

Cell Death and Disease

Volumn 5, Issue 4, 2014, Pages

  Chen, Z ^a   Wang, G ^a   Zhai, X ^a   Hu, Y ^a   Gao, D ^a   Ma, L ^a   Yao, J ^a   Tian, X ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Intestinal ischemia reperfusion; Oxidative stress

Indexed keywords

ADAPTOR PROTEIN; GLUTATHIONE; INTERLEUKIN 6; MALONALDEHYDE; MANGANESE SUPEROXIDE DISMUTASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C BETA; PROTEIN KINASE C BETA2; PROTEIN KINASE C INHIBITOR; PROTEIN P66; PROTEIN SHC; RUBOXISTAURIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; SHC1 PROTEIN, HUMAN; SHC1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD; CACO 2 CELL LINE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE SILENCING; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; INTESTINE INJURY; INTESTINE MUCOSA; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; SUPERIOR MESENTERIC ARTERY OBSTRUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL HYPOXIA; CELL MEMBRANE; DRUG EFFECTS; ENZYMOLOGY; HUMAN; INFLAMMATION; INSTITUTE FOR CANCER RESEARCH MOUSE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; VASCULARIZATION;

ANIMALS; APOPTOSIS; CACO-2 CELLS; CELL HYPOXIA; CELL MEMBRANE; ENZYME ACTIVATION; HUMANS; INFLAMMATION; INTESTINES; MALE; MICE, INBRED ICR; OXIDATIVE STRESS; PHOSPHORYLATION; PROTEIN KINASE C BETA; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; REPERFUSION INJURY; SHC SIGNALING ADAPTOR PROTEINS; TETRADECANOYLPHORBOL ACETATE;

EID: 84901028902     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.131     Document Type: Article

References (35)

1. Acosta S, Ogren M, Sternby NH, Bergqvist D, Bjorck M. Clinical implications for the management of acute thromboembolic occlusion of the superior mesenteric artery: autopsy findings in 213 patients. Ann Surg 2005; 241: 516-522.
2. Oldenburg WA, Lau LL, Rodenberg TJ, Edmonds HJ, Burger CD. Acute mesenteric ischemia: a clinical review. Arch Intern Med 2004; 164: 1054-1062.
3. Gibot S, Massin F, Alauzet C, Montemont C, Lozniewski A, Bollaert PE et al. Effects of the TREM-1 pathway modulation during mesenteric ischemia-reperfusion in rats. Crit Care Med 2008; 36: 504-510.
4. Wu B, Qiu W, Wang P, Yu H, Cheng T, Zambetti GP et al. p53 independent induction of PUMA mediates intestinal apoptosis in response to ischaemia-reperfusion. Gut 2007; 56: 645-654.
5. Chen Y, Lui VC, Rooijen NV, Tam PK. Depletion of intestinal resident macrophages prevents ischaemia reperfusion injury in gut. Gut 2004; 53: 1772-1780.
6. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998; 332: 281-292.
7. Tuo BG, Chow JY, Barrett KE, Isenberg JI. Protein kinase C potentiates cAMP-stimulated mouse duodenal mucosal bicarbonate secretion in vitro. Am J Physiol Gastrointest Liver Physiol 2004; 286: G814-G821.
8. Kong L, Andrassy M, Chang JS, Huang C, Asai T, Szabolcs MJ et al. PKCbeta modulates ischemia-reperfusion injury in the heart. Am J Physiol Heart Circ Physiol 2008; 294: H1862-H1870.
9. Fujita T, Asai T, Andrassy M, Stern DM, Pinsky DJ, Zou YS et al. PKCbeta regulates ischemia/reperfusion injury in the lung. J Clin Invest 2004; 113: 1615-1623.
10. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G et al. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. EMBO J 1997; 16: 706-716.
11. Migliaccio E, Giorgio M, Mele S, Pelicci G, Reboldi P, Pandolfi PP et al. The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature 1999; 402: 309-313.
12. Pacini S, Pellegrini M, Migliaccio E, Patrussi L, Ulivieri C, Ventura A et al. p66SHC promotes apoptosis and antagonizes mitogenic signaling in T cells. Mol Cell Biol 2004; 24: 1747-1757.
13. Zaccagnini G, Martelli F, Fasanaro P, Magenta A, Gaetano C, Di Carlo A et al. p66ShcA modulates tissue response to hindlimb ischemia. Circulation 2004; 109: 2917-2923.
14. Spescha RD, Shi Y, Wegener S, Keller S, Weber B, Wyss MM et al. Deletion of the ageing gene p66(Shc) reduces early stroke size following ischaemia/reperfusion brain injury. Eur Heart J 2013; 34: 96-103.
15. Carpi A, Menabo R, Kaludercic N, Pelicci P, Di Lisa F, Giorgio M. The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. Biochim Biophys Acta 2009; 1787: 774-780.
16. Nemoto S, Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002; 295: 2450-2452.
17. Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M et al. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. Science 2007; 315: 659-663.
18. Paneni F, Mocharla P, Akhmedov A, Costantino S, Osto E, Volpe M et al. Gene silencing of the mitochondrial adaptor p66(Shc) suppresses vascular hyperglycemic memory in diabetes. Circ Res 2012; 111: 278-289.
19. Inagaki K, Chen L, Ikeno F, Lee FH, Imahashi K, Bouley DM et al. Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation 2003; 108: 2304-2307.
20. Tanaka M, Terry RD, Mokhtari GK, Inagaki K, Koyanagi T, Kofidis T et al. Suppression of graft coronary artery disease by a brief treatment with a selective epsilonPKC activator and a deltaPKC inhibitor in murine cardiac allografts. Circulation 2004; 110: I194-I199.
21. Bright R, Mochly-Rosen D. The role of protein kinase C in cerebral ischemic and reperfusion injury. Stroke 2005; 36: 2781-2790.
22. Haga S, Terui K, Fukai M, Oikawa Y, Irani K, Furukawa H et al. Preventing hypoxia/ reoxygenation damage to hepatocytes by p66(shc) ablation: up-regulation of anti-oxidant and anti-apoptotic proteins. J Hepatol 2008; 48: 422-432.
23. Franzeck FC, Hof D, Spescha RD, Hasun M, Akhmedov A, Steffel J et al. Expression of the aging gene p66Shc is increased in peripheral blood monocytes of patients with acute coronary syndrome but not with stable coronary artery disease. Atherosclerosis 2012; 220: 282-286.
24. Shi Y, Cosentino F, Camici GG, Akhmedov A, Vanhoutte PM, Tanner FC et al. Oxidized low-density lipoprotein activates p66Shc via lectin-like oxidized low-density lipoprotein receptor-1, protein kinase C-beta, and c-Jun N-terminal kinase kinase in human endothelial cells. Arterioscler Thromb Vasc Biol 2011; 31: 2090-2097.
25. Sukhotnik I, Brod V, Lurie M, Rahat MA, Shnizer S, Lahat N et al. The effect of 100% oxygen on intestinal preservation and recovery following ischemia-reperfusion injury in rats. Crit Care Med 2009; 37: 1054-1061.
26. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-247.
27. Gertz M, Steegborn C. The Lifespan-regulator p66Shc in mitochondria: redox enzyme or redox sensor? Antioxid Redox Signal Antioxid Redox Signal 2010; 13: 1417-1428.
28. Beltrami E, Ruggiero A, Busuttil R, Migliaccio E, Pelicci PG, Vijg J et al. Deletion of p66Shc in mice increases the frequency of size-change mutations in the lacZ transgene. Aging Cell 2013; 12: 177-183.
29. Xiong Y, Yu Y, Montani JP, Yang Z, Ming XF. Arginase-II induces vascular smooth muscle cell senescence and apoptosis through p66Shc and p53 independently of its l-arginine ureahydrolase activity: implications for atherosclerotic plaque vulnerability. J Am Heart Assoc 2013; 2: e96.
30. Arany I, Faisal A, Clark JS, Vera T, Baliga R, Nagamine Y. p66SHC-mediated mitochondrial dysfunction in renal proximal tubule cells during oxidative injury. Am J Physiol Renal Physiol 2010; 298: F1214-F1221.
31. Grootjans J, Hundscheid IH, Lenaerts K, Boonen B, Renes IB, Verheyen FK et al. Ischaemia-induced mucus barrier loss and bacterial penetration are rapidly counteracted by increased goblet cell secretory activity in human and rat colon. Gut 2013; 62: 250-258.
32. Aiello LP, Vignati L, Sheetz MJ, Zhi X, Girach A, Davis MD et al. Oral protein kinase c beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C beta Inhibitor- Diabetic Retinopathy Study and the Protein Kinase C beta Inhibitor-Diabetic Retinopathy Study 2. Retina 2011; 31: 2084-2094.
33. Tuttle KR, McGill JB, Haney DJ, Lin TE, Anderson PW. Kidney outcomes in long-term studies of ruboxistaurin for diabetic eye disease. Clin J Am Soc Nephrol 2007; 2: 631-636.
34. Chiu CJ,McArdle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low-flow states. I. A morphological, hemodynamic, and metabolic reappraisal. Arch Surg 1970; 101: 478-483.
35. Baylor AR, Diebel LN, Liberati DM, Dulchavsky SA, Brown WJ, Diglio CA. The synergistic effects of hypoxia/reoxygenation or tissue acidosis and bacteria on intestinal epithelial cell apoptosis. J Trauma 2003; 55: 241-247; 247-248.